Accumulating evidence has shown that abnormal m6A levels mediated by METTL3 are involved in the malignant progression of lung cancer, including cell proliferation, invasion, metastasis, angiogenesis, drug resistance, glycolysis, cancer stem cells, and tumor environment [24–26]. The gene discussed is METTL3; the disease is cancer.